[{"id":"88783755-7459-4207-a7a6-0af081a9d60d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496976","created_at":"2021-01-18T06:16:27.062Z","updated_at":"2025-02-25T13:48:06.671Z","phase":"Phase 2","brief_title":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","source_id_and_acronym":"NCT01496976","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD20 • CD5","pipe":"","alterations":" ","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Arzerra (ofatumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/30/2012","start_date":" 03/30/2012","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 03/25/2025","study_completion_date":" 03/25/2025","last_update_posted":"2025-02-21"},{"id":"ed362182-add1-434a-b6df-44f932cad804","acronym":"","url":"https://clinicaltrials.gov/study/NCT02135133","created_at":"2021-01-18T09:54:33.334Z","updated_at":"2025-02-25T13:11:11.926Z","phase":"Phase 2","brief_title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","source_id_and_acronym":"NCT02135133","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD19 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD19 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zydelig (idelalisib) • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 10/06/2020","study_completion_date":" 10/06/2020","last_update_posted":"2024-10-16"},{"id":"da7c1c4e-12fb-4361-97e1-5845011e3482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243190","created_at":"2021-01-18T05:00:24.541Z","updated_at":"2025-02-25T13:16:23.958Z","phase":"Phase 2","brief_title":"Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT01243190","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH • CD38","pipe":" | ","alterations":" CD38 positive","tags":["IGH • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 03/28/2023","study_completion_date":" 03/28/2023","last_update_posted":"2024-09-19"},{"id":"15d10f06-e62d-4c96-9c37-1d6b5cfefc74","acronym":"NCI-2014-01707","url":"https://clinicaltrials.gov/study/NCT02199184","created_at":"2021-01-18T10:16:59.275Z","updated_at":"2024-07-02T16:34:27.417Z","phase":"Phase 2","brief_title":"Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02199184 - NCI-2014-01707","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2024-06-11"},{"id":"adf70f50-0fc0-4474-a764-ea766f835694","acronym":"","url":"https://clinicaltrials.gov/study/NCT01286272","created_at":"2021-01-18T05:13:11.418Z","updated_at":"2024-07-02T16:35:02.742Z","phase":"Phase 2","brief_title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01286272","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":"","alterations":" ","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 04/08/2011","start_date":" 04/08/2011","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-05-17"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"c6fc72ec-918c-4d87-82e5-708aa1f2978a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01361711","created_at":"2021-01-18T05:34:18.032Z","updated_at":"2025-02-25T13:16:51.580Z","phase":"Phase 2","brief_title":"Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01361711","lead_sponsor":"Northwestern University","biomarkers":" CD20 • CD5 • CD52 • FCER2","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD5 • CD52 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • Arzerra (ofatumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 08/17/2015","primary_completion_date":" 08/17/2015","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-03-27"},{"id":"d5be950f-3675-484f-9cf0-33481c11c95d","acronym":"NCI-2011-03562","url":"https://clinicaltrials.gov/study/NCT01527149","created_at":"2021-01-18T06:26:25.305Z","updated_at":"2024-07-02T16:35:20.370Z","phase":"Phase 2","brief_title":"Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01527149 - NCI-2011-03562","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/06/2011","start_date":" 12/06/2011","primary_txt":" Primary completion: 04/26/2018","primary_completion_date":" 04/26/2018","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-07"},{"id":"ea8050eb-dcd2-46de-a3ee-648924a2cb0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01145209","created_at":"2021-01-18T04:33:23.618Z","updated_at":"2025-02-25T13:15:58.228Z","phase":"Phase 2","brief_title":"Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL","source_id_and_acronym":"NCT01145209","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD5","pipe":" | ","alterations":" CD20 expression","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Arzerra (ofatumumab) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2023-11-28"},{"id":"31ca75f3-dc09-454f-8ab2-63ffcb8b2778","acronym":"","url":"https://clinicaltrials.gov/study/NCT01060384","created_at":"2021-01-18T04:10:35.097Z","updated_at":"2025-02-25T13:15:35.019Z","phase":"Phase 1/2","brief_title":"Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT01060384","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 03/29/2010","start_date":" 03/29/2010","primary_txt":" Primary completion: 10/25/2016","primary_completion_date":" 10/25/2016","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2023-10-04"},{"id":"917c2805-5f04-496c-b017-e050f4e87dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01768338","created_at":"2021-01-18T07:46:52.906Z","updated_at":"2025-02-25T15:40:34.527Z","phase":"Phase 1","brief_title":"Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma","source_id_and_acronym":"NCT01768338","lead_sponsor":"Michael John Robertson","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab) • iboctadekin (SB-485232)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 08/03/2017","study_completion_date":" 08/03/2017","last_update_posted":"2023-02-10"},{"id":"cf6cefb3-e325-4004-a027-f1a9f42095c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01555541","created_at":"2021-01-18T06:35:08.814Z","updated_at":"2025-02-25T13:17:36.729Z","phase":"Phase 2","brief_title":"Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT01555541","lead_sponsor":"C. Babis Andreadis","biomarkers":" CD20 • CD34","pipe":"","alterations":" ","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 05/25/2012","start_date":" 05/25/2012","primary_txt":" Primary completion: 07/06/2017","primary_completion_date":" 07/06/2017","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2022-06-29"},{"id":"f5821b87-a4fd-4f5f-b740-69ab8422f09c","acronym":"FIL_MIRO","url":"https://clinicaltrials.gov/study/NCT02710643","created_at":"2021-01-18T13:15:10.822Z","updated_at":"2024-07-02T16:36:08.555Z","phase":"Phase 2","brief_title":"\"MIRO\" Molecularly Oriented Immuno-radio-therapy","source_id_and_acronym":"NCT02710643 - FIL_MIRO","lead_sponsor":"Fondazione Italiana Linfomi ONLUS","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 positive","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 04/07/2022","study_completion_date":" 04/07/2022","last_update_posted":"2022-06-21"},{"id":"75ee8123-2821-44b2-a4bb-5e4356c39cc4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01455051","created_at":"2021-01-18T06:02:34.027Z","updated_at":"2025-02-25T13:17:12.417Z","phase":"Phase 2","brief_title":"Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT01455051","lead_sponsor":"Grupo Espanol de trasplantes hematopoyeticos y terapia celular","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2022-05-06"},{"id":"cb6eee34-6ffe-41f5-af13-0b1b9a52d6f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01481272","created_at":"2021-01-18T06:11:06.595Z","updated_at":"2024-07-02T16:36:19.160Z","phase":"Phase 2","brief_title":"Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients","source_id_and_acronym":"NCT01481272","lead_sponsor":"Polish Lymphoma Research Group","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • leucovorin calcium • Arzerra (ofatumumab) • mesna • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2021-12-27"},{"id":"00fa481a-a24e-4b36-b5e0-b34edd51ff50","acronym":"","url":"https://clinicaltrials.gov/study/NCT01190449","created_at":"2021-01-18T04:45:42.817Z","updated_at":"2024-07-02T16:36:26.179Z","phase":"Phase 2","brief_title":"Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01190449","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 positive • CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 10/15/2020","study_completion_date":" 10/15/2020","last_update_posted":"2021-08-18"},{"id":"11161d23-fd17-4b1c-87d3-f15d1b988566","acronym":"","url":"https://clinicaltrials.gov/study/NCT01613300","created_at":"2021-01-18T06:54:34.306Z","updated_at":"2024-07-02T16:36:29.774Z","phase":"Phase 2","brief_title":"Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients","source_id_and_acronym":"NCT01613300","lead_sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 04/04/2012","start_date":" 04/04/2012","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2021-05-26"},{"id":"f9a992a2-3271-4572-9b33-9620244567ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT01363128","created_at":"2021-01-18T05:34:50.878Z","updated_at":"2024-07-02T16:36:30.863Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","source_id_and_acronym":"NCT01363128","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • Arzerra (ofatumumab) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 07/12/2011","start_date":" 07/12/2011","primary_txt":" Primary completion: 04/08/2020","primary_completion_date":" 04/08/2020","study_txt":" Completion: 04/08/2020","study_completion_date":" 04/08/2020","last_update_posted":"2021-05-03"},{"id":"11ddd352-e8ec-4657-880c-cac535ceac65","acronym":"","url":"https://clinicaltrials.gov/study/NCT01497496","created_at":"2021-01-18T06:16:43.639Z","updated_at":"2025-02-25T14:33:12.891Z","phase":"Phase 2","brief_title":"Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","source_id_and_acronym":"NCT01497496","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD20 • CD5","pipe":"","alterations":" ","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 01/26/2012","start_date":" 01/26/2012","primary_txt":" Primary completion: 09/25/2019","primary_completion_date":" 09/25/2019","study_txt":" Completion: 03/20/2020","study_completion_date":" 03/20/2020","last_update_posted":"2021-04-27"},{"id":"1c29941e-ecbb-448e-a4a0-6f3c40fc3c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01329900","created_at":"2021-01-18T05:25:15.053Z","updated_at":"2025-02-25T15:51:48.160Z","phase":"Phase 2","brief_title":"Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT01329900","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2 • CD20 • CCND1","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ifosfamide • etoposide IV • Arzerra (ofatumumab) • mesna • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/22/2011","start_date":" 08/22/2011","primary_txt":" Primary completion: 07/21/2019","primary_completion_date":" 07/21/2019","study_txt":" Completion: 07/21/2019","study_completion_date":" 07/21/2019","last_update_posted":"2020-07-08"},{"id":"6979fb67-c31f-4bb1-8fbc-4931fdb19608","acronym":"","url":"https://clinicaltrials.gov/study/NCT00824265","created_at":"2021-01-18T03:08:04.661Z","updated_at":"2024-07-02T16:36:44.060Z","phase":"Phase 3","brief_title":"Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00824265","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD5","pipe":"","alterations":" ","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Arzerra (ofatumumab) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 365","initiation":"Initiation: 03/12/2009","start_date":" 03/12/2009","primary_txt":" Primary completion: 12/17/2014","primary_completion_date":" 12/17/2014","study_txt":" Completion: 10/25/2017","study_completion_date":" 10/25/2017","last_update_posted":"2020-06-18"},{"id":"cd8ddc9b-b091-4f86-9e99-cd528d4c1459","acronym":"CLL2-BIO","url":"https://clinicaltrials.gov/study/NCT02689141","created_at":"2021-01-18T13:06:54.959Z","updated_at":"2025-02-25T15:53:12.103Z","phase":"Phase 2","brief_title":"Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)","source_id_and_acronym":"NCT02689141 - CLL2-BIO","lead_sponsor":"German CLL Study Group","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • bendamustine • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 02/04/2016","start_date":" 02/04/2016","primary_txt":" Primary completion: 07/13/2017","primary_completion_date":" 07/13/2017","study_txt":" Completion: 02/06/2020","study_completion_date":" 02/06/2020","last_update_posted":"2020-06-11"},{"id":"155f14b0-469c-45ed-80bd-2fe82acb9cc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01024010","created_at":"2021-01-18T04:00:59.484Z","updated_at":"2024-07-02T16:37:06.781Z","phase":"Phase 2","brief_title":"Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01024010","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • IGH • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Arzerra (ofatumumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 09/28/2017","study_completion_date":" 09/28/2017","last_update_posted":"2018-09-18"},{"id":"84acf406-f5ea-4a5a-97a1-343423d38e5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01294579","created_at":"2021-01-18T05:15:29.419Z","updated_at":"2024-07-02T16:37:08.034Z","phase":"Phase 2","brief_title":"Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)","source_id_and_acronym":"NCT01294579","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 05/17/2011","start_date":" 05/17/2011","primary_txt":" Primary completion: 12/20/2016","primary_completion_date":" 12/20/2016","study_txt":" Completion: 12/20/2016","study_completion_date":" 12/20/2016","last_update_posted":"2018-08-09"}]